PMID- 37059988
OWN - NLM
STAT- MEDLINE
DCOM- 20230419
LR  - 20230419
IS  - 1471-2334 (Electronic)
IS  - 1471-2334 (Linking)
VI  - 23
IP  - 1
DP  - 2023 Apr 14
TI  - Omadacycline for treatment of acute bacterial infections: a meta-analysis of 
      phase II/III trials.
PG  - 232
LID - 10.1186/s12879-023-08212-0 [doi]
LID - 232
AB  - OBJECTIVE: This study aims to assess the clinical efficacy and safety of 
      omadacycline for the treatment of acute bacterial infections. METHODS: A search 
      of PubMed, Embase, Cochrane Library, and Clinical Trials was conducted up to July 
      1, 2022. We included only randomized controlled trials (RCTs), in which 
      omadacycline and other antibiotics were evaluated for treating acute bacterial 
      infections in adults. The primary outcomes were clinical response and 
      microbiological response, whereas the secondary outcome was the risk of adverse 
      events (AEs). RESULTS: A total of seven RCTs involving 2841 patients with acute 
      bacterial infection were included. Overall, our study illustrated that the 
      clinical cure ratio of omadacycline was similar to the comparators in the 
      treatment of acute bacterial infections (OR = 1.18, 95%CI = 0.96, 1.46, 
      I(2) = 29%). Omadacycline had a microbiological eradication rate similar to 
      comparators in the treatment of acute bacterial infections (OR = 1.02, 
      95%CI = 0.81, 1.29, I(2) = 42%). No statistical differences were observed between 
      omadacycline and the comparators in terms of infection caused by Staphylococcus 
      aureus (OR = 1.14, 95%CI = 0.80, 1.63, I(2) = 0%), methicillin-resistant S. 
      aureus (MRSA, OR = 1.28, 95%CI = 0.73, 2.24, I(2) = 0%), methicillin-susceptible 
      S. aureus (MSSA, OR = 1.12, 95%CI = 0.69, 1.81, I(2) = 0%), and Enterococcus 
      faecalis (OR = 2.47, 95%CI = 0.36, 16.97, I(2) = 7%). A significant difference 
      was found between omadacycline and the comparators for the risk of any AEs and 
      treatment related AEs. The risk of discontinuation of the study drug due to an 
      AEs was lower for omadacycline than for the comparators. CONCLUSION: Omadacycline 
      is as good as comparators in terms of efficacy and tolerance in the treatment of 
      acute bacterial infections in adult patients. Thus, omadacycline is an 
      appropriate option for antibiotic therapy in adult patients with acute bacterial 
      infections.
CI  - (c) 2023. The Author(s).
FAU - Lin, Fei
AU  - Lin F
AD  - Department of Pharmacy, The First Affiliated Hospital of Chengdu Medical College, 
      Chengdu, China.
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, China.
FAU - He, Rong
AU  - He R
AD  - Department of Respiratory and Critical Care Medicine, The First Affiliated 
      Hospital of Chengdu Medical College, Chengdu, China.
FAU - Yu, Bin
AU  - Yu B
AD  - Department of Pharmacy, Mianyang Central Hospital, Mianyang, China.
FAU - Deng, Bowen
AU  - Deng B
AD  - Department of Pharmacy, The Sixth People's Hospital of Chengdu, Chengdu, China.
FAU - Ling, Baodong
AU  - Ling B
AD  - School of Pharmacy, Chengdu Medical College, Chengdu, China. 
      lingbaodong@cmc.edu.cn.
FAU - Yuan, Mingyong
AU  - Yuan M
AD  - Clinical Medical College, Chengdu Medical College, Chengdu, China. 
      yuanmingyong@cmc.edu.cn.
AD  - Outpatient Department, The First Affiliated Hospital of Chengdu Medical College, 
      Chengdu, China. yuanmingyong@cmc.edu.cn.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20230414
PL  - England
TA  - BMC Infect Dis
JT  - BMC infectious diseases
JID - 100968551
RN  - 0 (Anti-Bacterial Agents)
RN  - 090IP5RV8F (omadacycline)
RN  - 0 (Tetracyclines)
SB  - IM
MH  - Adult
MH  - Humans
MH  - Anti-Bacterial Agents/adverse effects
MH  - *Bacterial Infections/drug therapy
MH  - *Staphylococcal Infections/microbiology
MH  - Tetracyclines/adverse effects
MH  - Treatment Outcome
MH  - Clinical Trials, Phase II as Topic
MH  - Clinical Trials, Phase III as Topic
PMC - PMC10105466
OTO - NOTNLM
OT  - Acute bacterial infections
OT  - Meta-analysis, Efficacy, Safety
OT  - Omadacycline
COIS- All authors declare no conflict of interest.
EDAT- 2023/04/15 06:00
MHDA- 2023/04/18 06:41
PMCR- 2023/04/14
CRDT- 2023/04/14 23:33
PHST- 2022/10/20 00:00 [received]
PHST- 2023/04/01 00:00 [accepted]
PHST- 2023/04/18 06:41 [medline]
PHST- 2023/04/14 23:33 [entrez]
PHST- 2023/04/15 06:00 [pubmed]
PHST- 2023/04/14 00:00 [pmc-release]
AID - 10.1186/s12879-023-08212-0 [pii]
AID - 8212 [pii]
AID - 10.1186/s12879-023-08212-0 [doi]
PST - epublish
SO  - BMC Infect Dis. 2023 Apr 14;23(1):232. doi: 10.1186/s12879-023-08212-0.